Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Cardiac T2* value · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
MIC · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
LVEF (echocardiography) · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Ferritin (µg/L) · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Liver T2* value · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
LIC · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Adverse events · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Pulmonary exacerbations · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Nutrition and growth Change in: a) weight (kg) b) BMI (kg/m2) c) height (m) · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Sweat chloride level ‐ change from baseline Scale: mmol/L · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Mortality rate · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Incidence of S pneumoniae infection Isolated bacterial infection · children with SCD
Summary of findings ‐ initiation of penicillin prophylaxis may leads to lower incidence of S pneumoniae infection Isolated bacterial infection compared with placebo (low certainty).
1 finding from 1 review
Antibiotic‐resistant organisms isolated · children with SCD who have been receiving prophylactic penicillin for at least two years
1 finding from 1 review
Requirement of other courses of antibiotics · children with SCD who have been receiving prophylactic penicillin for at least two years
Summary of findings ‐ withdrawal of penicillin prophylaxis showed no clear difference in requirement of other courses of antibiotics compared with continuation (low certainty).
1 finding from 1 review
Compliance with treatment · children with SCD who have been receiving prophylactic penicillin for at least two years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found